CancerDrs

Lung Cancer clinical trials in New York

109 actively recruiting lung cancer trials at 45 sites across New York.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 2 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full lung cancer transparency page →

Phase 3 Recruiting NIH

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04267848
Sites in New York:
  • Hematology Oncology Associates of Central New York-Auburn — Auburn, New York
  • Northwell Health Imbert Cancer Center — Bay Shore, New York
  • Maimonides Medical Center — Brooklyn, New York
  • Roswell Park Cancer Institute — Buffalo, New York
  • Hematology Oncology Associates of CNY at Camillus — Camillus, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizuma…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06096844
Sites in New York:
  • Glens Falls Hospital — Glens Falls, New York
  • Upstate Cancer Center at Oswego — Oswego, New York
  • University of Rochester — Rochester, New York
  • Stony Brook University Medical Center — Stony Brook, New York
  • State University of New York Upstate Medical University — Syracuse, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-sm…

Sponsor: Pfizer
NCT ID: NCT07222566
Sites in New York:
  • New York Oncology Hematology — Albany, New York
  • New York Oncology Hematology — Clifton Park, New York
  • Hematology Oncology Associates of Rockland — Nyack, New York
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates fo…

Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT04613596
Sites in New York:
  • New York Oncology Hematology - Albany Medical Center — Albany, New York
  • Local Institution - Unk077 — Rhinebeck, New York
  • Montefiore Medical Center — The Bronx, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

This phase III trial compares the effect of atezolizumab (or atezolizumab and recombinant human hyaluronidase) to standard observation for preventing cancer return after surgery (recurrence) in patients who have undergone a complete surgic…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07388524
Sites in New York:
  • Roswell Park Cancer Institute — Buffalo, New York
  • Hematology Oncology Associates of CNY at Camillus — Camillus, New York
  • Hematology Oncology Associates of Central New York-East Syracuse — East Syracuse, New York
  • Stony Brook University Medical Center — Stony Brook, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.

Sponsor: Summit Therapeutics
NCT ID: NCT06767514
Sites in New York:
  • Clinical Study Site — New York, New York
  • Clinical Study Site — Syracuse, New York
  • Clinical Site — The Bronx, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if ol…

Sponsor: Eli Lilly and Company
NCT ID: NCT06890598
Sites in New York:
  • Columbia University Irving Medical Center — New York, New York
  • Memorial Sloan Kettering Cancer Center — New York, New York
  • Northport VA Medical Center — Northport, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with locally advanced or …

Sponsor: AstraZeneca
NCT ID: NCT06627647
Sites in New York:
  • Research Site — Buffalo, New York
  • Research Site — Westbury, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if this approa…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06686771
Sites in New York:
  • Northwell Health/Center for Advanced Medicine — Lake Success, New York
  • Mount Sinai Chelsea — New York, New York
  • Mount Sinai West — New York, New York
  • Mount Sinai Hospital — New York, New York
  • Manhattan Eye Ear and Throat Hospital — New York, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-muta…

Sponsor: Hoffmann-La Roche
NCT ID: NCT06793215
Sites in New York:
  • SUNY Upstate Medical University — Syracuse, New York
  • Montefiore Einstein Cancer Center — The Bronx, New York
  • Clinical Research Alliance — Westbury, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced o…

Sponsor: AstraZeneca
NCT ID: NCT06357533
Sites in New York:
  • Research Site — Stony Brook, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal flui…

Sponsor: NRG Oncology
NCT ID: NCT06500481
Sites in New York:
  • NYU Langone Hospital - Brooklyn — Brooklyn, New York
  • Memorial Sloan Kettering Commack — Commack, New York
  • Memorial Sloan Kettering Westchester — Harrison, New York
  • NYU Langone Hospital - Long Island — Mineola, New York
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone — New York, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT06561386
Sites in New York:
  • Local Institution - 0356 — Hawthorne, New York
  • Veterans Affairs New York Harbor Healthcare System — New York, New York
  • Local Institution - 0380 — Northport, New York
  • University of Rochester Medical Center — Rochester, New York
  • Local Institution - 0511 — Schenectady, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. The primary hypothesis of this study is sacituzumab tir…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06312137
Sites in New York:
  • Cayuga Medical Center ( Site 0086) — Ithaca, New York
  • University Hospital at Stony Brook ( Site 0054) — Stony Brook, New York
  • White Plains Hospital ( Site 0091) — White Plains, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

TROPION-Lung17 will measure the efficacy and safety of datopotamab deruxtecan (Dato-DXd) compared with docetaxel in patients with trophoblast cell surface protein 2 (TROP2) positive advanced or metastatic lung cancer without actionable gen…

Sponsor: AstraZeneca
NCT ID: NCT07291037
Sites in New York:
  • Research Site — East Syracuse, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting o…

Sponsor: Pierre Fabre Medicament
NCT ID: NCT03394365
Sites in New York:
  • Weill Cornell Medicine (Adults only) — New York, New York
  • Columbia University Medical Center (Adults and Pediatrics) — New York, New York
  • Memorial Sloan Kettering Cancer Center (Adults and Pediatrics) — New York, New York
  • Montefiore Medical Center (Adults only) — The Bronx, New York
  • Montefiore Medical Center (Pediatrics only) — The Bronx, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.

Sponsor: Zai Lab (Shanghai) Co., Ltd.
NCT ID: NCT07218146
Sites in New York:
  • Stony Brook Cancer Center — Stony Brook, New York
  • Montefiore Medical Center — The Bronx, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

This study will assess the effect of Dato-DXd in combination with osimertinib or Dato-DXd monotherapy versus platinum-based doublet chemotherapy in terms of progression-free survival (PFS).

Sponsor: AstraZeneca
NCT ID: NCT06417814
Sites in New York:
  • Research Site — New York, New York
  • Research Site — New York, New York
  • Research Site — The Bronx, New York
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy

Sponsor: Bristol-Myers Squibb
NCT ID: NCT07100080
Sites in New York:
  • Perlmutter Cancer Center at NYU Langone Hospital - Long Island — Mineola, New York
  • NYU Langone Health — New York, New York
  • Weill Cornell Medical College — New York, New York
  • Rochester General Hospital Infectious Disease — Rochester, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutations. Advanced NSCLC means lung cancer …

Sponsor: Bayer
NCT ID: NCT06452277
Sites in New York:
  • R.J. Zuckerberg Cancer Center — New Hyde Park, New York
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

This is a study to evaluate the safety and efficacy of EIK1001 administered intravenously in combination with pembrolizumab and histologically appropriate chemotherapy for patients with stage 4 NSCLC.

Sponsor: Eikon Therapeutics
NCT ID: NCT07365319
Sites in New York:
  • NYU Langone Hospital Long Island — Mineola, New York
  • NYU Langone Hospital Manhattan — New York, New York
  • Jacobi Medical Center - Albert Einstein College of Medicine — The Bronx, New York
  • White Plains Hospital — White Plains, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

Researchers are looking for new ways to treat locally advanced non-small cell lung cancer (NSCLC) that is unresected and has a gene mutation called KRAS G12C. Researchers want to learn if calderasib (MK-1084) can be given with durvalumab, …

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07554339
Sites in New York:
  • New York Oncology Hematology P.C ( Site 9000) — Albany, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis

This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on the prevention of Cancer-Associated Thrombosis (CAT) in participants. The aim of the study is to see how effective the study drug…

Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT07410117
Sites in New York:
  • Memorial Sloan Kettering Cancer Center — New York, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers

This study is researching an experimental drug called REGN7508 (called "study drug") and will consist of 2 parts: Part 1 and Part 2. The study is focused on participants with or without cancer who develop blood clots in certain veins (call…

Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT07493304
Sites in New York:
  • Memorial Sloan Kettering Cancer Center — New York, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)

This phase III trial compares the effect of the combination of aglatimagene besadenovec and pembrolizumab versus standard of care docetaxel chemotherapy for the treatment of stage IV non-squamous, non-small cell lung cancer. Aglatimagene b…

Sponsor: Candel Therapeutics, Inc.
NCT ID: NCT07660094
Sites in New York:
  • Laura & Isaac Perlmutter Cancer Center at NYU Langone Health — New York, New York
View on ClinicalTrials.gov →

Showing 25 of 109 trials with sites in New York. See all lung cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-12